METTL3 Inhibitor

METTL3-IN-11 is an excellent, selective METTL3 inhibitor (IC₅₀ = 45.31 nM). METTL3-IN-11 exhibits high selectivity towards METTL3 compared to DNMT1, EZH1, MLL1, and PRMT1. METTL3-IN-11 reduces the m6A level of total RNA in MOLM-13 and SKOV3 cells, induces cell apoptosis, and inhibits cell migration. METTL3-IN-11 can reduce the expression of m6A downstream target genes (c-MYC and BCL2). METTL3-IN-11 can be used for the study of ovarian cancer and acute myeloid leukemia.

AN-465 is a METTL3 inhibitor with an IC₅₀ of 1.782 μM and a K_d of 8.75 μM against human METTL3. AN-465 reduces m₆A modification of RNA, including EV71 2C region RNA, and disrupts the interaction between METTL3 and EV71 2C RNA. AN-465 decreases EV71-induced proinflammatory cytokine production, modulates immune cell phenotypes, alleviates EV71-induced apoptosis, restores autophagic flux, and reduces viral particle formation. AN-465 is used in the study of hand, foot and mouth disease.

7OQL (compound 54) is a selective METTL3 inhibitor (IC₅₀=0.054 µM). 7OQL has the potential to be used in the study of cancer.

METTL3-IN-13 is a METTL3 inhibitor. METTL3-IN-13 is applicable to the research of multiple cancers such as hypopharyngeal squamous cell carcinoma and non-small cell lung cancer.

STM2457 (Standard) is the analytical standard of STM2457 (HY-134836). This product is intended for research and analytical applications. STM2457 is a first-in-class, highly potent, selective and orally active METTL3 inhibitor with an IC₅₀ of 16.9 nM. STM2457 can be used for the research of acute myeloid leukaemia (AML).